Search

Your search keyword '"O'Connell, Abby"' showing total 2 results
Start Over Author "O'Connell, Abby" Database OAIster
2 results on '"O'Connell, Abby"'

1. BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial

Author

Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectious Diseases, Epi Infectieziekten Team 1, Messina, Nicole L, Pittet, Laure F, McDonald, Ellie, Moore, Cecilia, Barry, Simone, Bonten, Marc, Byrne, Anthony, Campbell, John, Croda, Julio, Croda, Mariana G, Dalcolmo, Margareth, de Almeida E Val, Fernando F, de Oliveira, Roberto D, Dos Santos, Glauce, Douglas, Mark W, Gardiner, Kaya, Gwee, Amanda, Jardim, Bruno A, Kollmann, Tobias, Lacerda, Marcus Vg, Lucas, Michaela, Lynn, David J, Manning, Laurens, Marshall, Helen, O'Connell, Abby, Perrett, Kirsten P, Post, Jeffrey J, Prat-Aymerich, Cristina, Rocha, Jorge L, Rodriguez-Baño, Jesus, Wadia, Ushma, Warris, Adilia, Davidson, Andrew, Curtis, Nigel, BRACE trial Consortium Group, Epi Infectieziekten, Infection & Immunity, Epidemiology of Sepsis & Inflammation in Critically Ill Patients, JC onderzoeksprogramma Infectious Diseases, Epi Infectieziekten Team 1, Messina, Nicole L, Pittet, Laure F, McDonald, Ellie, Moore, Cecilia, Barry, Simone, Bonten, Marc, Byrne, Anthony, Campbell, John, Croda, Julio, Croda, Mariana G, Dalcolmo, Margareth, de Almeida E Val, Fernando F, de Oliveira, Roberto D, Dos Santos, Glauce, Douglas, Mark W, Gardiner, Kaya, Gwee, Amanda, Jardim, Bruno A, Kollmann, Tobias, Lacerda, Marcus Vg, Lucas, Michaela, Lynn, David J, Manning, Laurens, Marshall, Helen, O'Connell, Abby, Perrett, Kirsten P, Post, Jeffrey J, Prat-Aymerich, Cristina, Rocha, Jorge L, Rodriguez-Baño, Jesus, Wadia, Ushma, Warris, Adilia, Davidson, Andrew, Curtis, Nigel, and BRACE trial Consortium Group

Published
2024

2. Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers

Author

Bill & Melinda Gates Foundation, Minderoo Foundation, Royal Children's Hospital Foundation, National Health and Medical Research Council (Australia), Swiss National Science Foundation, European Molecular Biology Laboratory, Medical Research Council (UK), Health Services Union New South Wales Branch, Peter Sowerby Foundation, SA Health, Insurance Advisernet Foundation, NAB Foundation, Calvert-Jones Foundation, Modara Pines Charitable Foundation, United Health Foundation, Epworth HealthCare, Victoria State Government, Pittet, Laure F., Messina, Nicole L., Orsini, Francesca, Moore, Cecilia L., Abruzzo, Veronica, Barry, Simone, Bonnici, Rhian, Bonten, Marc, Campbell, John, Croda, Julio, Dalcolmo, Margareth, Gardiner, Kaya, Gell, Grace, Germano, Susie, Gomes-Silva, Adriano, Goodall, Casey, Gwee, Amanda, Jamieson, Tenaya, Jardim, Bruno, Kollmann, Tobias R., Lacerda, Marcus V. G., Lee, Katherine J., Lucas, Michaela, Lynn, David J., Manning, Laurens, Marshall, Helen S., McDonald, Ellie, Munns, Craig F., Nicholson, Suellen, O’Connell, Abby, Oliveira, Roberto D. de, Perlen, Susan, Perrett, Kirsten P., Prat-Aymerich, Cristina, Richmond, Peter C., Rodríguez-Baño, Jesús, Santos, Glauce dos, Silva, Patricia V. da, Teo, Jia Wei, Villanueva, Paola, Warris, Adilia, Wood, Nicholas J., Davidson, Andrew, Curtis, Nigel, BRACE Trial Consortium Group, Bill & Melinda Gates Foundation, Minderoo Foundation, Royal Children's Hospital Foundation, National Health and Medical Research Council (Australia), Swiss National Science Foundation, European Molecular Biology Laboratory, Medical Research Council (UK), Health Services Union New South Wales Branch, Peter Sowerby Foundation, SA Health, Insurance Advisernet Foundation, NAB Foundation, Calvert-Jones Foundation, Modara Pines Charitable Foundation, United Health Foundation, Epworth HealthCare, Victoria State Government, Pittet, Laure F., Messina, Nicole L., Orsini, Francesca, Moore, Cecilia L., Abruzzo, Veronica, Barry, Simone, Bonnici, Rhian, Bonten, Marc, Campbell, John, Croda, Julio, Dalcolmo, Margareth, Gardiner, Kaya, Gell, Grace, Germano, Susie, Gomes-Silva, Adriano, Goodall, Casey, Gwee, Amanda, Jamieson, Tenaya, Jardim, Bruno, Kollmann, Tobias R., Lacerda, Marcus V. G., Lee, Katherine J., Lucas, Michaela, Lynn, David J., Manning, Laurens, Marshall, Helen S., McDonald, Ellie, Munns, Craig F., Nicholson, Suellen, O’Connell, Abby, Oliveira, Roberto D. de, Perlen, Susan, Perrett, Kirsten P., Prat-Aymerich, Cristina, Richmond, Peter C., Rodríguez-Baño, Jesús, Santos, Glauce dos, Silva, Patricia V. da, Teo, Jia Wei, Villanueva, Paola, Warris, Adilia, Wood, Nicholas J., Davidson, Andrew, Curtis, Nigel, and BRACE Trial Consortium Group

Abstract

[BACKGROUND] The bacille Calmette–Guérin (BCG) vaccine has immunomodulatory “off-target” effects that have been hypothesized to protect against coronavirus disease 2019 (Covid-19)., [METHODS] In this international, double-blind, placebo-controlled trial, we randomly assigned health care workers to receive the BCG-Denmark vaccine or saline placebo and followed them for 12 months. Symptomatic Covid-19 and severe Covid-19, the primary outcomes, were assessed at 6 months; the primary analyses involved the modified intention-to-treat population, which was restricted to participants with a negative test for severe acute respiratory syndrome coronavirus 2 at baseline., [RESULTS] A total of 3988 participants underwent randomization; recruitment ceased before the planned sample size was reached owing to the availability of Covid-19 vaccines. The modified intention-to-treat population included 84.9% of the participants who underwent randomization: 1703 in the BCG group and 1683 in the placebo group. The estimated risk of symptomatic Covid-19 by 6 months was 14.7% in the BCG group and 12.3% in the placebo group (risk difference, 2.4 percentage points; 95% confidence interval [CI], −0.7 to 5.5; P=0.13). The risk of severe Covid-19 by 6 months was 7.6% in the BCG group and 6.5% in the placebo group (risk difference, 1.1 percentage points; 95% CI, −1.2 to 3.5; P=0.34); the majority of participants who met the trial definition of severe Covid-19 were not hospitalized but were unable to work for at least 3 consecutive days. In supplementary and sensitivity analyses that used less conservative censoring rules, the risk differences were similar but the confidence intervals were narrower. There were five hospitalizations due to Covid-19 in each group (including one death in the placebo group). The hazard ratio for any Covid-19 episode in the BCG group as compared with the placebo group was 1.23 (95% CI, 0.96 to 1.59). No safety concerns were identified., [CONCLUSIONS] Vaccination with BCG-Denmark did not result in a lower risk of Covid-19 among health care workers than placebo. (Funded by the Bill and Melinda Gates Foundation and others; BRACE ClinicalTrials.gov number, NCT04327206.)

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results